- Home
- PSNL vs TSHA Comparison
PSNL vs TSHA Comparison
Compare PSNL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | TSHA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | TSHA |
|---|---|---|
| Price | $16.03 | $4.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $15.17 | $13.00 |
| AVG Volume (30 Days) | 1.9M | ★ 3.4M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,648,000.00 | $9,773,000.00 |
| Revenue This Year | $21.10 | N/A |
| Revenue Next Year | $30.66 | $1,023.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $4.96 | $3.69 |
| 52 Week High | $18.89 | $7.30 |
Technical Indicators
Market Signals| Indicator | PSNL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 33.09 |
| Support Level | $15.96 | $4.37 |
| Resistance Level | $16.39 | $4.72 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 32.11 | 24.08 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.